Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.…
Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
Zai Lab (NASDAQ: ZLAB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,784 employees.
The shares were at 21.03 USD on 20 November 2026, down 4.4% over 52 weeks. Its 52-week range is 15.96 USD to 29.02 USD: the price is 27.5% below the high and 31.8% above the low.
Its market capitalisation is 2.63B USD.
Zai Lab reports return on equity of -24.5%, an operating margin of -63.0% and revenue down 6.8% year over year.
It holds more cash than debt, a net cash position of 292.21M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 12 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 34.21 USD is 62.7% above the current price. The next earnings report is expected on 25 February 2027.